Meeting
2023 ASCO Genitourinary Cancers Symposium
Pelvic clinical node-positive prostate cancer: Impact of radiotherapy and nodal disease burden.
Authors
Tony Felefly
The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
Tony Felefly , Alborz Jooya , Selena Laprade , Soumyajit Roy , Shawn Malone , Scott C. Morgan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 338)
DOI
10.1200/JCO.2023.41.6_suppl.338
Abstract #
338
Poster Bd #
L16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer.
First Author: Nicholas George Nickols
Poster
2020 Genitourinary Cancers Symposium
Predicting long-term results with circulating tumor cells in patients with de novo androgen sensitive prostate cancer treated with hTERT peptides vaccine.
First Author: Wolfgang Lilleby
Poster
2018 Genitourinary Cancers Symposium
Survival after surgical or radiotherapeutic treatment for high-risk localized prostate cancer: A National Cancer Database analysis with comprehensive treatment group imbalances adjustments.
First Author: Ronald D. Ennis
Poster
2017 Genitourinary Cancers Symposium
Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial.
First Author: David Frazier Jarrard